Search Results

You searched for: rituximab

SMC Advice

  • tofacitinib (Xeljanz)
    SMC Drug ID: 1298/18; Manufacturer: Pfizer Ltd; Indication: In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.; Submission Type: Full submission; Status: Restricted; Date Advice Published:  12/02/2018;
  • baricitinib (Olumiant)
    SMC Drug ID: 1265/17; Manufacturer: Eli Lilly and Company Ltd; Indication: Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.; Submission Type: Full submission; Status: Restricted; Date Advice Published:  11/09/2017;
  • ibrutinib (Imbruvica)
    SMC Drug ID: 1258/17; Manufacturer: Janssen-Cilag Ltd; Indication: In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy.; Submission Type: Non submission; Status: Not Recommended; Date Advice Published:  12/06/2017;
  • obinutuzumab (Gazyvaro)
    SMC Drug ID: 1219/17; Manufacturer: Roche; Indication: In combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.; Submission Type: Full submission; Status: Accepted; Date Advice Published:  13/03/2017;
  • bortezomib (Velcade)
    SMC Drug ID: 1075/15; Manufacturer: Janssen-Cilag Ltd; Indication: In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation; Submission Type: Full submission; Status: Accepted; Date Advice Published:  07/09/2015;

More results from the SMC Advice section

Forthcoming Submissions

About SMC

  • SMC Minutes - Tuesday, 3 October 2006
    Minutes of the SMC Meeting held on Tuesday 3 October 2006 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow G1 2NP Present: Professor David Webb (Chairman); Professor James ...
  • SMC Minutes 5th July 2011
    Minutes of the SMC Meeting held on Tuesday 05 July 2011 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Ms Angela Timoney (Chairman), Ms Sandra Auld, ...
  • SMC Minutes Tuesday 7 September 2010
    Minutes of the SMC Meeting held on Tuesday 07 September 2010 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Ms Angela Timoney (Chairman), Mrs Laura ...
  • SMC Minutes: Tuesday 2 November 2010
    Minutes of the SMC Meeting held on Tuesday 02 November 2010 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present:  Professor Ken Paterson (Chairman), Dr Ke...
  • Minutes of the SMC Meeting held on Tuesday 4 August 2009
    Minutes of the SMC Meeting held on Tuesday 4 August 2009 NHS Quality Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present: Professor Ken Paterson (Chairman), Mrs Laura Ace...

More results from the About SMC section

Help on how to improve your search.